Intrexon Corp (XON) - NYSE
  • Aug. 12, 2015, 7:49 AM
    • Intrexon (NYSE:XON) acquires UK-based Oxitec Limited for $80M in cash and $80M in XON common stock.
    • Oxitec is a pioneer in using advanced genetics and molecular biology to control insect populations via the production of sterile, self-limiting insects whose offspring do not survive. Its main focus is controlling disease-propagating mosquitoes and pest-related crop damage.
    • The transaction is expected to close later this year.
    | Aug. 12, 2015, 7:49 AM | 2 Comments
  • Feb. 13, 2015, 8:29 AM
    • Intrexon (NYSE:XON) acquires ActoGenix, a Belgian clinical stage biopharma company that is developing a class of products called ActoBiotics, based on the molecular engineering of food-grade microbes (Lactococcus lactis).
    • ActoBiotics combine the selectivity and low toxicity of protein-based biopharmaceuticals with the added benefits of oral availability and cost-effective formulation and manufacturing. Its lead product candidates are AG013, a therapeutic peptide for the prevention and attenuation of oral mucositis, and AG014 which secretes anti-TNF-alpha Fab (antibody) to treat inflammatory bowel disease.
    • Under the terms of the acquisition agreement, Intrexon will pay $30M in cash and $30M in Intrexon stock. The transaction is expected to close this quarter.
    | Feb. 13, 2015, 8:29 AM | 1 Comment
  • Jan. 26, 2015, 12:30 PM
    • Synthetic biology leader Intrexon (XON +2.9%) acquires the remaining stake in Exemplar Genetics, a developer of a broad line of transgenic swine models used in the research and development of a variety of diseases. Financial terms are undisclosed.
    | Jan. 26, 2015, 12:30 PM
  • Jul. 2, 2014, 11:07 AM
    • Intrexon (XON +2.5%) enters into a definitive agreement to acquire Trans Ova Genetics, a provider of genetic cattle breeding services. The acquisition will broaden XON's reach in animal health and productivity.
    • Under the terms of the agreement, Trans Ova shareholders will receive $60M in upfront cash, $30M in XON common stock and deferred payments of up to $20M. Trans Ova delivered net income of $~4.9M on revenues of $63.3M in 2013.
    • Intrexon expects the transaction to close in Q3.
    | Jul. 2, 2014, 11:07 AM
  • Mar. 7, 2014, 9:06 AM
    • Intrexon (XON) finalizes its buy of Medistem, a developer of endometrial regenerative cells (ERC). The company believes that ERCs can potentially be manufactured as genetically modified therapeutics delivery vehicles in the body.
    • 116 mutual funds have positions in the stock.
    | Mar. 7, 2014, 9:06 AM
  • Dec. 20, 2013, 3:55 PM
    • Shares of Intrexon (XON +1.4%) look to close modestly higher after the company's $26M deal for California-based Medistem (MEDS +47.7%) which develops Endometrial Regenerative Cells.
    • XON says the cells "have the potential to provide treatments for conditions such as cancer, wound healing, and cardiovascular disease," when combined with integrated synthetic biology platforms.
    • More specifically, XON plans to "develop two powerful classes of clinical products": Engineered stem cells for "therapeutic delivery of secreted proteins" and for "producing exosomes."
    • MEDS shareholders are getting $0.27 in cash and "$1.08 worth of XON common stock." (PR)
    | Dec. 20, 2013, 3:55 PM
Company Description
Intrexon Corp. is a biotechnology company focused on collaborating with companies in health, food, energy and the environment to create biologically based products. The company is engaged in the field of synthetic biology, which is an emerging discipline that applies engineering principles to... More
Sector: Healthcare
Industry: Medical Appliances & Equipment
Country: United States